A large multinational pharmaceutical company, formally entered the field of equipment

　　Pharmaceutical Network Enterprise News : Recently, AstraZeneca and Xinyun Heng An Medical Technology (Beijing) Co., Ltd officially signed a contract to act as an agent of the Xinyun Heng'an medical-grade twelve-in-line electrocardiogram CONX BEP186 domestic sales business At this point, AstraZeneca, a well-known multinational biopharmaceutical company, has entered the field of equipment in its localization innovation process
Studies have shown that ischemic risk events in heart attack patients continue to increase even after PCI interventional surgery, with a readmission rate of up to 10.8% 30 days after surgery Therefore, PCI patients' postoperative management is particularly important, and home electrocardiogram monitoring is an effective auxiliary means of patient stoma management
This time, AstraZeneca agent's twelve-conductive eynomecmeter CONX BEP186, is mainly aimed at patients after transdermal coronary interventional surgery (PCI) to provide a complete solution for home electrocardiogram monitoring to improve patient post-hospital management
As the first pharmaceutical company to participate in the construction of China's chest pain center, to later explore the practice of chest pain center city-wide model, AstraZeneca in the heart of the concept of patient-centered, in the field of cardiovascular has always adhered to the construction of closed-loop whole disease course innovation management platform, and has been in the hospital and hospital in the course of disease management progress and achievements This time, for the post-hospital link in the whole course management, AstraZeneca has incorporated a 12-conduction electrocardiogram and a complete solution for home electrocardiogram monitoring, which will achieve a complete closed loop around patients with acute coronary syndrome (ACS, including myocardial infarction and unstable angina) from pre-hospital first aid, hospital treatment to post-hospital rehabilitation
In fact, in recent years, the pharmaceutical industry production costs and industrial concentration continue to improve, increasingly fierce competition Coupled with the gradual improvement of various medical reform policies, the government's drug production, price control has been greatly strengthened, pharmaceutical enterprises generally in the domestic began to encounter development bottlenecks In this case, in order to achieve better development, some pharmaceutical companies have increased their innovation efforts, and some pharmaceutical companies have been able to broaden their product lines
Because of the data show that China's medical device industry market size has nearly trillion yuan, the average annual growth rate of more than 25%, far beyond the growth of the pharmaceutical industry, the industry has broad prospects Therefore, many pharmaceutical companies have just begun to dabble in the medical and health industry, trying to seize the new blue sea of the great health era Among them, domestic pharmaceutical companies in these years to the field of medical devices into the action is more frequent
Broad Medicine Group, for example, has been accelerating the layout of medical devices since several years ago On September 12, 2017, Guangpharma Baiyunshan International Medical Device Innovation Park was established in Huangpu District, Guangzhou City, and the operator Guangzhou Zhongcheng Medical Device Industry Development Co., Ltd was unveiled on the same day The park is the "13th Five-Year Plan" of Guang pharmaceutical group to develop the medical device industry's important support platform, currently aimed at the industry in the high-end, the development of high-performance medical devices
In addition, Fosun Pharma has also had a wide range of applications in the medical field over the years In addition to medical research and development, in circulation, medical performance In 2017, Fosun took a 90 million-dollar stake in The Swedish medical device company Brea Medical Group, buying an 80 percent stake in The Swedish medical device company Brea Medical Group, and then jointly established a $100 million joint venture with U.S Intuitive to develop the Da Vinci surgical robot
Recently, Zhongheng Group also announced that it will increase its capital to Zhongheng Medical by 970 million yuan, with a cumulative capital of 1 billion yuan registered to enter the field of emergency medical supplies Some industry analysts said that Zhongheng Group's move into medical devices is more of a transformation altogether under pressure from Chinese medicine injections
In general, in the face of domestic volume procurement, medical insurance catalog adjustment and other new policy new situation, many in the pharmaceutical enterprises have been affected, are thinking about how Nirvana rebirth, prominent re-encirclement, some choose layout of innovative drugs, some choose mergers and acquisitions, some choose industrial chain integration, and for the medical device field layout, the search for drug integration synergy, now appears to be a potential direction, but also a major focus of pharmaceutical companies focus.